Identification immune response genes in psoriasis after treatment with secukinumab

BACKGROUND: Secukinumab is a fully human IgG1κ MoAb that selectively binds to IL-17A with high affinity, and it has been proven effective for the treatment of psoriasis. However, the immune response pathways and mechanisms during the treatment are still masked. Therefore, the current study was desig...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jing, Liu, Yufang, Zhang, Yuxin, Wang, Shiyan, Kang, Shaomei, Mi, Ningyu, Li, Ruxin, Zou, Yulin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082531/
https://www.ncbi.nlm.nih.gov/pubmed/37029373
http://dx.doi.org/10.1186/s12920-023-01507-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082531/
https://www.ncbi.nlm.nih.gov/pubmed/37029373
http://dx.doi.org/10.1186/s12920-023-01507-w

Ejemplares similares